Page last updated: 2024-12-05

3,4-epoxy-1-butene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4-Epoxy-1-butene is a highly reactive organic compound. Its synthesis involves the epoxidation of 1-butene, often using a peroxyacid like m-chloroperoxybenzoic acid. The compound is of interest due to its role as an intermediate in various organic reactions, particularly in the production of other epoxides and polymers. Its reactivity arises from the strained three-membered ring of the epoxide group, making it susceptible to ring-opening reactions. 3,4-Epoxy-1-butene has been explored in the context of polymer synthesis, with the potential to form polymers with unique properties. However, due to its reactivity, it is typically not used directly in applications but rather serves as a building block for more stable derivatives.'

3,4-epoxy-1-butene: RN given refers to monomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13586
CHEMBL ID1299388
MeSH IDM0082602

Synonyms (74)

Synonym
nsc-8023
ethenyloxirane
butadiene oxide
1,2-epoxy-3-butene
butadiene monoepoxide
3,4-epoxy-1-butene
wln: t3otj b1u1
1,2-oxido-3-butene
1,3-butadiene oxide
butadiene monooxide
butadiene monoxide
butadiene epoxide
vinylethylene oxide
1,2-epoxybutene-3
3,4-epoxybut-1-ene
vinyloxirane
930-22-3
nsc8023
1-butene,4-epoxy-
oxirane, ethenyl-
1-butene, 3,4-epoxy-
nsc24251
nsc-24251
NCGC00091691-01
monoepoxybutene
monoepoxybutadiene
einecs 213-210-4
1,2-epoxybutene
ai3-16049
nsc 24251
3,4-epoxybutene
nsc 8023
hsdb 5520
ccris 2614
3,4-epoxy-1-butene, 98%
2-vinyloxirane
2-ethenyloxirane
1,3-butadiene monoepoxide
E0337
CHEMBL1299388
AKOS005257726
NCGC00091691-02
vinyl oxirane
478err5nkr ,
oxirane, 2-ethenyl-
unii-478err5nkr
dtxcid105240
cas-930-22-3
tox21_200871
dtxsid4025240 ,
NCGC00258425-01
FT-0623293
3,4-epoxy-1-butene [hsdb]
(+/-)-vinyloxirane
1,3-butadiene monooxide
vinyl epoxide
3,4-epoxy-butene-1
1,3-butadiene monoxide
1,2-epoxybut-3-ene
J-640021
2-vinyloxirane #
3,4-epoxybutene-1
1,2-epoxy-3-butylene
mfcd00005149
J-800015
26703-03-7
BBL102661
STL556465
FT-0773954
FT-0771178
Q15910431
AMY40815
D90487
EN300-98979

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" All three compounds showed signs of toxicity, with DEB being substantially more toxic than either CEO or EB."( In vitro genotoxicity testing of (1-chloroethenyl)oxirane, a metabolite of beta-chloroprene.
Donner, EM; Gladnick, NL; Himmelstein, MW; Snyder, RD; Valentine, R, 2001
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" A physiologically based pharmacokinetic model of the uptake, tissue distribution, and metabolism of butadiene was constructed to determine if the biochemical kinetic constants obtained from in vitro studies are consistent with the observed in vivo uptake and metabolism."( Species differences in the production and clearance of 1,3-butadiene metabolites: a mechanistic model indicates predominantly physiological, not biochemical, control.
Kohn, MC; Melnick, RL, 1993
)
0.29
" To investigate this possibility a physiologically based pharmacokinetic (pbpk) model for BU together with its first reactive metabolite 1,2-epoxybutene-3 (butadiene monoxide, BMO) was developed."( A physiologically based pharmacokinetic model for butadiene and its metabolite butadiene monoxide in rat and mouse and its significance for risk extrapolation.
Filser, JG; Johanson, G, 1993
)
0.29
"In vitro and in vivo butadiene (BD) metabolism data from laboratory animals were integrated into a rodent physiologically based pharmacokinetic (PBPK) model with flow- and diffusion-limited compartments."( Physiologically based pharmacokinetic modeling of blood and tissue epoxide measurements for butadiene.
Himmelstein, MW; Medinsky, MA; Schlosser, PM; Sweeney, LM, 1996
)
0.29
" To achieve this objective, known pathways of 1,2-epoxy-3-butene (butadiene monoepoxide; BMO) and BDE metabolism were incorporated into a physiologically based pharmacokinetic model by scaling rates determined in vitro."( Physiologically based pharmacokinetic modeling of 1,3-butadiene, 1,2-epoxy-3-butene, and 1,2:3,4-diepoxybutane toxicokinetics in mice and rats.
Bond, JA; Medinsky, MA; Schlosser, PM; Sweeney, LM, 1997
)
0.3

Dosage Studied

ExcerptRelevanceReference
" The dose-response for BMO followed a second order curve at this time interval, with maximum MN induction at the dose of 186 mumol/kg and lower induction of higher doses."( Germ cell mutagenicity of three metabolites of 1,3-butadiene in the rat: induction of spermatid micronuclei by butadiene mono-, di-, and diolepoxides in vivo.
Lähdetie, J; Peltonen, K; Sjöblom, T, 1997
)
0.3
" For the BMO studies, rats were dosed with 71, 143, or 286 mumol/kg BMO (n = 3 for each dose group)."( Disposition of butadiene epoxides in Sprague-Dawley rats.
Bond, JA; Boogaard, PJ; Medinsky, MA; Sweeney, LM; Turner, MJ; Valentine, JL, 1997
)
0.3
" The methods developed in this work provide the means to study accumulation, repair and dose-response relationships of BD-DNA adducts in vivo."( Quantitative analysis of 1,3-butadiene-induced DNA adducts in vivo and in vitro using liquid chromatography electrospray ionization tandem mass spectrometry.
Chiang, SY; Swenberg, JA; Walker, VE, 1998
)
0.3
" The dose-response for mutations induced at the cII locus was essentially equal after DEB exposure of BBM1 and BBR1 fibroblasts."( Micronuclei and gene mutations in transgenic big Blue((R)) mouse and rat fibroblasts after exposure to the epoxide metabolites of 1, 3-butadiene.
Erexson, GL; Tindall, KR, 2000
)
0.31
" The dose-response relationship for the formation of adduct G4 was approximately linear for all tissues studied for both rats and mice exposed in the 1-20 ppm range."( Dose responses for DNA adduct formation in tissues of rats and mice exposed by inhalation to low concentrations of 1,3-[2,3-[(14)C]-butadiene.
Booth, ED; Kilgour, JD; Robinson, SA; Watson, WP, 2004
)
0.32
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency22.38720.004023.8416100.0000AID485290
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency22.68630.003041.611522,387.1992AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency1.13700.001530.607315,848.9004AID1224849
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (144)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (9.03)18.7374
1990's83 (57.64)18.2507
2000's36 (25.00)29.6817
2010's10 (6.94)24.3611
2020's2 (1.39)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.68 (24.57)
Research Supply Index5.04 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (2.60%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other150 (97.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]